CA19-9
- Aliases
-
- CA 19.9
- CA19-9
- CA199
- cancer antigen 19-9
- carbohydrate antigen 19-9
- Description
- CA19-9 is a monoclonal antibody that was first discovered in the serum of patients with colon cancer. Since that time CA19-9 has been used as a tumor marker for a variety of cancers.
Attributes
- QA State
- Accepted
- Type
- Protein
- Certifications
-
- None
- QA State for Breast
- Curated
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Ovary
- Accepted
Organ-Specific Notes
CA19-9 may be a molecular marker for ovarian cancer. Literature suggests that the concomitant measurement of CA19-9 with CA125 could offer some benefit in the monitoring of patients for the recurrence of ovarian carcinoma.
Performance Comment
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CA19-9 alone was not a strong predictor.
Supporting Study Data
PLCO Ovarian Phase III Validation Study
Study phase on the ovary: 3
Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study. Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.
View ProtocolDecision rule: PMID:21372037
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
Study phase on the ovary: 3
Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a “working consensus panel” for subsequent analysis in PLCO specimens.
View ProtocolDecision rule: PMID:21372037
Ovary-Specific Protocols
- No organ-level protocols specified for ovary.
Ovary-Specific Publications
- No organ-level publications were listed for ovary.
Ovary-Specific Resources
- No organ-level resources were given for ovary.
- Certifications
-
- None
- QA State for Pancreas
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Prostate
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- A Biomarker Bakeoff in Early Stage Pancreatic Cancer
- Biomarkers for Prostate and Bladder Cancer
- Breast Reference Set Application: Anu Mathew-Meso Scale (2012)
- Breast Reference Set Application: GeorgeTuszynski-Temple (2012)
- PLCO Ovarian Phase III Validation Study
- Pancreatic Cancer Bake Off 2
- Pancreatic Reference Set Application: Brian Haab-Van Andel (2012)
- Pancreatic Reference Set Application: Ivan Blasutig-University of Toronto (2014)
- Pancreatic Reference Set Application: Kazufumi Honda-National Cancer Center (2014)
- Pancreatic Reference Set Application: Samir Hanash-MD Anderson (2017)
- Pancreatic Reference Set Application:Sumio Ohtsuki/Kazfumi Honda-Kumamoto University (2019)
- Pre-diagnostic Pancreatic Cancer Set Aside Project
- SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
- A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
- Analysis of prostate cancer by proteomics using tissue specimens.
- CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
- Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
- Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma.
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
- No resources were specified for this biomarker.